注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
4D Molecular Therapeutics Inc是一家臨床階段的基因治療公司。該公司專注於基於腺相關病毒(AAV)載體的靶向療法的開發。該公司的產品候選集中在各個領域,包括眼科、心髒病和肺病。該公司的候選產品包括4D-125、4D-150、4D-110、4D-310和4D-710。4D-125用於治療帶有色素性視網膜炎GTP酶調節劑 (RPGR) 基因的X連鎖色素性視網膜炎 (XLRP) 患者。4D-150是為治療濕齡相關黃斑變性 (wet-AMD) 而開發的。4D-110用於治療無脈絡膜症。4D-310是為法布里病的全身治療而開發的。該公司正在開發4D-710,用於治療廣泛的囊性纖維化患者,不依賴於囊性纖維化跨膜電導調節劑 (CFTR)。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
John F. Milligan | 60 | 2020 | Executive Chairman |
Nancy Miller-Rich | 63 | 2020 | Independent Director |
Jacob M. Chacko | 43 | 2019 | Independent Director |
David H. Kirn | 60 | 2013 | Co-Founder, CEO & Director |
Daniel F. Takefman | 56 | 2023 | Member of Scientific Advisory Board |
Paul J. Utz | - | 2023 | Member of Scientific Advisory Board |
Amy Rosenberg | - | 2023 | Member of Scientific Advisory Board |
Ronal Crystal | - | 2023 | Member of Scientific Advisory Board |
Amit Gaggar | - | 2023 | Member of Scientific Advisory Board |
Richard B. Moss | - | 2023 | Member of Scientific Advisory Board |
Ramesh Shivdasani | - | - | Member of the Scientific Advisory Board |
Ronald G. Crystal | - | - | Member of the Scientific Advisory Board |
Douglas Hanahan | - | - | Member of the Scientific Advisory Board |
Charles P. Theuer | 60 | 2015 | Independent Director |
Shawn Cline Tomasello | 65 | 2020 | Independent Director |
Susannah Gray | 63 | 2020 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核